← Leaderboards
Kirk Edward Hevener
Idaho State University
$975,668
Attributed
$1,206,084
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,667,542 · 4
By mechanism
R21$913,096 · 3
R01$754,446 · 1
Top collaborators
- Julian G Hurdle6 shared
- Sasanka S Chukkapalli4 shared
Others in their field
Top investigators on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Randall J Bateman · Washington University$83,824,814
- Stuart L Schreiber · Harvard University (Medical School)$49,424,554
- Jay D Keasling · University Of California-Berkeley$47,558,861
- David Heimbrook · Leidos Biomedical Research, Inc.$47,513,682
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
EnzymesMicrobiologyStructural BiologyBiochemicalOxidoreductasePathway InteractionsFatty AcidsMembraneMetronidazoleMicrobiotaBiologicalIntestinesInsightAnti-Bacterial AgentsClostridium DifficileAntibioticsIsoenzymesIn VivoAcyl Carrier ProteinEvaluationPreventBacteriaDrug TargetingOrganism
Grant awards (7)
Development of Microbiome-Sparing Antibacterials for Clostridioides difficile Infection$754,446
R01 · FY2025 · AI · contact PI
Evaluation of a microbiota-sparing therapeutic concept for periodontal disease, involving removal of pathogenic Porphyromonas and Fusobacterium$191,250
R21 · FY2025 · DE
Evaluation of a microbiota-sparing therapeutic concept for periodontal disease, involving removal of pathogenic Porphyromonas and Fusobacterium$27,583
R21 · FY2025 · DE
ConProject-001$27,583
R21 · FY2025 · DE
Evaluation of a microbiota-sparing therapeutic concept for periodontal disease, involving removal of pathogenic Porphyromonas and Fusobacterium$242,625
R21 · FY2024 · DE
Investigation of the FAS-II enzyme, FabK, as a druggable target for C. difficile$232,158
R21 · FY2017 · AI · contact PI
Investigation of the FAS-II enzyme, FabK, as a druggable target for C. difficile$191,897
R21 · FY2016 · AI · contact PI